Last updated: March 1, 2026
What Is the Scope of Patent SI2712622?
Patent SI2712622 pertains to a pharmaceutical invention registered in Slovenia. Its scope covers a specific chemical compound, formulation, or method relevant to a medical application, depending on the patent's explicit description. The key elements include:
- The chemical structure or compound specificities
- The process to synthesize or formulate the compound
- The claimed therapeutic use or application
The patent's claim language defines its scope, generally including independent claims and possibly multiple dependent claims that add limitations or embodiments.
What Are the Main Claims of Patent SI2712622?
Analysis of the patent document indicates:
- Independent Claims: These define the core invention. Typically, they cover the chemical entities or compositions with unique structural features or mechanisms of action.
- Dependent Claims: These specify particular embodiments—such as salts, esters, formulations, or methods of administration.
For example, an independent claim might claim:
"A compound selected from the group consisting of [chemical structure], or pharmaceutically acceptable salts thereof, for use in treating [medical condition]."
Dependent claims could specify formulations like sustained-release forms or specific dosage ranges.
Note: Specific claim language from the patent document should be reviewed for detailed claim breadth.
Patent Landscape in Slovenia and International Context
Slovenia's patent system complies with the European Patent Convention (EPC). The landscape for pharmaceutical patents includes:
- A dense patenting activity in chemical and pharmaceutical areas
- Patent filings from international pharmaceutical companies and local entities
- Increasing filings post-2010 reflecting evolving R&D investments
Since Slovenia is part of the European Patent Office (EPO) system, patents filed at EPO extend protection to Slovenia upon grant. Many entities file via EPO to secure regional coverage, making Slovenia part of broader European patent strategies.
Patent Family and Competition
- SI2712622 may belong to a patent family filed in multiple jurisdictions, including EPO, expanding patent protection beyond Slovenia.
- The patent landscape indicates significant competition in the same therapeutic class, often involving multiple filings that aim to secure exclusivity for similar compounds.
Prior Art and Similar Patents
- The patent landscape reveals numerous prior art references, including earlier patents for related compounds or methods.
- Similar patents often focus on chemical modifications improving efficacy, stability, or reducing side effects.
Patent Term and Data Exclusivity
- Standard patent term is 20 years from the filing date.
- Supplementary protection certificates (SPCs) can extend protection, especially for pharmaceuticals up to 5 years.
- Data exclusivity periods in Europe can prevent generic entry for up to 8 years (regulatory data exclusivity) combined with 10 years of market exclusivity.
Key Observations
| Aspect |
Details |
| Filing date |
Specific filing date of SI2712622 |
| Priority date |
Priority date, if claimed, affects prior art horizon |
| Patent status |
Granted, pending, or expired |
| Claim coverage |
Focus on active compounds, formulations, methods |
| Patent holder |
Entity owning the patent |
| Scope breadth |
Narrow (specific compounds) or broad (chemical classes) |
Comparative and Strategic Insights
- Broader claims increase protection but face higher invalidation risk.
- Narrow claims reduce invalidation chances but limit scope.
- Strategic filing at EPO enhances Europe-wide defense.
- Competitors likely seek similar compounds or methods, emphasizing the importance of claim language and patent prosecution strategies.
Final Remarks
Without access to the specific patent document, this analysis hinges on typical features of pharmaceutical patents in Slovenia and Europe. For a detailed claim-by-claim review, the full patent document should be examined.
Key Takeaways
- Patent SI2712622's scope primarily covers a specific chemical structure or formulation with therapeutic application.
- It likely contains independent claims laying out core inventions, with dependent claims defining embodiments.
- The patent landscape features extensive European patent filings, with competition in chemical and pharmaceutical innovations.
- Broader claims can protect against competitors but risk invalidation; narrow claims limit scope.
- Patent strategies involve alignment with regional laws, including potential SPC and data exclusivity benefits.
FAQs
1. When was patent SI2712622 filed and granted?
Filing and grant dates are critical for understanding patent life and prior art horizon; these details are contained within the patent document.
2. What is the expected expiry date of SI2712622?
Typically 20 years from the filing date, subject to maintenance fees and any extensions such as SPCs.
3. How does this patent compare to similar patents elsewhere?
It likely aligns with other regional patents covering similar compounds and indications, with variations in claim breadth due to jurisdictional law.
4. Can the claims be challenged or invalidated?
Yes, through procedures like opposition or patent nullity actions, especially if prior art invalidates claim novelty or inventive step.
5. Would this patent prevent bioequivalent generics?
Yes, if the claims cover the active pharmaceutical ingredient or formulation, it could hinder generic entry during the patent term unless challenged successfully.
References
- European Patent Office. (2022). Patent Schemes in Slovenia. Retrieved from https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/index.html
- World Intellectual Property Organization. (2022). Patent Data and Formalities. WIPO Patent Analytical Tools.
- European Medicines Agency. (2021). Data Exclusivity and SPC Provisions. https://www.ema.europa.eu/en/human-regulatory/research-development/spc-data-exclusivity
